David Colleran's Insider Trades & SAST Disclosures
David Colleran's most recent trade in Anika Therapeutics Inc. was a trade of 28,165 Restricted Stock Unit done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Colleran.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 28,165 | 28,165 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 13,669 | 13,669 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 6,448 | 12,897 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 6,448 | 49,847 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.91 per share. | 14 Mar 2025 | 1,893 | 47,954 (0%) | 0% | 15.9 | 30,118 | Common Stock |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 7,663 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 7,663 | 45,649 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.79 per share. | 11 Mar 2025 | 2,250 | 43,399 (0%) | 0% | 16.8 | 37,778 | Common Stock |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,465 | 39,590 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,465 | 5,465 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran B. | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.62 per share. | 10 Mar 2025 | 1,604 | 37,986 (0%) | 0% | 16.6 | 26,658 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 46,875 | 46,875 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 19,345 | 19,345 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 7,662 | 35,245 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 7,662 | 7,663 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,465 | 10,930 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,465 | 29,188 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 3,682 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 3,682 | 24,804 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.79 per share. | 11 Mar 2024 | 2,250 | 32,995 (0%) | 0% | 25.8 | 58,028 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 1,605 | 27,583 (0%) | 0% | 25.4 | 40,799 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 1,081 | 23,723 (0%) | 0% | 25.4 | 27,479 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,663 | 15,325 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,663 | 22,538 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 10 Mar 2023 | 2,250 | 20,288 (0%) | 0% | 26.1 | 58,725 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 35,790 | 35,790 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 16,395 | 16,395 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 3,683 | 3,682 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 3,683 | 15,956 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.91 per share. | 09 Mar 2023 | 1,081 | 14,875 (0%) | 0% | 26.9 | 29,090 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2023 | 2,500 | 13,007 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2023 | 2,500 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.59 per share. | 04 Mar 2023 | 734 | 12,273 (0%) | 0% | 31.6 | 23,187 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Purchase of securities on an exchange or from another person at price $ 21.37 per share. | 11 May 2022 | 1,500 | 9,867 (0%) | 0% | 21.4 | 32,055 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Purchase of securities on an exchange or from another person at price $ 26.65 per share. | 14 Mar 2022 | 1,500 | 8,367 (0%) | 0% | 26.7 | 39,978 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 35,864 | 35,864 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 22,988 | 22,988 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 3,682 | 7,365 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 3,682 | 7,948 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.22 per share. | 09 Mar 2022 | 1,081 | 6,867 (0%) | 0% | 26.2 | 28,344 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 2,500 | 5,000 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 2,500 | 2,500 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.06 per share. | 04 Mar 2022 | 734 | 4,266 (0%) | 0% | 31.1 | 22,798 | Common Stock |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 27,681 | 27,681 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 11,047 | 11,047 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 2,500 | 2,500 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 2,500 | 5,000 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges